Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865290 · ClinicalTrials.gov registry record · Phase 2
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
A Phase 2 study of Diabetes Mellitus and Indigestion, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03865290 is a Phase 2 study of Diabetes Mellitus and Indigestion that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 150 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03865290, a Phase 2 study of Diabetes Mellitus and Indigestion, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ondansetron 8mg
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03865290
The ClinicalTrials.gov registry entry for NCT03865290 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03865290 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03865290 about?
NCT03865290 is a clinical study titled "Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia". Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondanset...
What is the current status of trial NCT03865290?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2019-04-02. Estimated completion is 2028-03.
What conditions does trial NCT03865290 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Indigestion.
What interventions are being tested in trial NCT03865290?
The interventions under investigation include: Placebo (DRUG), Ondansetron 8mg (DRUG).
Who is sponsoring clinical trial NCT03865290?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03865290 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.